DELIVER Study: DELiverability of the Resolute Integrity Stent in All-Comer Vessels and Cross-OvER Stenting
Sponsored by Medtronic Vascular
About this trial
Last updated 12 years ago
Study ID
IP992
Status
Completed
Type
Observational
Placebo
No
Accepting
18+ Years
All Sexes
Trial Timing
Ended 13 years ago
What is this trial about?
The primary objective of the DELIVER Study is to assess the deliverability of the Resolute Integrity Stent as primary stent or as a secondary cross-over stent following delivery failure of another stent type in real world patients.
What are the participation requirements?
Inclusion Criteria
* Minimum legal age (18)
* Acceptable candidate for treatment with a drug-eluting stent in accordance with applicable guidelines
* Patient has consented to participate and authorized in writing the collection and release of medical information
Exclusion Criteria
* Pregnancy
* Participating in another study that interferes with study endpoints
* Untreatable hypersensitivity or allergies to aspirin, heparin, clopidogrel, zotarolimus or similar drugs or contrast media
* Patients in whom anti-platelet and/or anticoagulation therapy is contraindicated